Y-mAbs Therapeutics (YMAB) Tops Q2 EPS by 10c, beats revenue, offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: YMAB) | Delayed: 8.61 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.61 | 52 Week High | $ | |||
| Open | $8.61 | 52 Week Low | $ | |||
| Day High | $8.61 | P/E | N/A | |||
| Day Low | $8.61 | EPS | $ | |||
| Volume | 2,531,499 | |||||
